14-3-3η Protein in serum and synovial fluid correlates with radiographic damage and progression in a longitudinal evaluation of patients with established rheumatoid arthritis. Issue 4 (3rd July 2020)

• Record Type: Journal Article
• Authors: Hammam, Nevin; Salah, Shaimaa; Kholef, Emad F.; Moussa, Ehab M.; Marotta, Anthony
• Is Part Of: Modern rheumatology. Volume 30:Issue 4(2020)
• Page Start: 664
• Page End: 670
• Publication Date: 2020-07-03
• Subjects: 14-3-3η Protein -- DAS-28 -- radiographic damage -- progression -- rheumatoid arthritis -- synovial fluid; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/14397595.2019.1637575
• Languages: English
• ISSNs: 1439-7595

Abstract

Abstract: Objectives: The aim of the study is to examine the association between 14-3-3η protein levels in both serum and synovial fluid (SF) with various parameters in a longitudinal cohort of patients with established rheumatoid arthritis (RA). Methods: Serum and SF samples were obtained from RA patients and 14-3-3η levels were measured. Radiological damage and progression were evaluated using Sharp/van der Heijde score (SHS) at study entry and at 2-years follow-up. Results : A total of 39 RA patients were included with a mean disease duration of 9.6 ± 8 years. Levels of 14-3-3η were two-fold higher in SF than in serum (mean of 3.7 versus 1.7 ng/mL, respectively). While no significant association was found between 14-3-3η levels with disease activity or other laboratory assessments, both serum and SF 14-3-3η levels positively correlated with radiographic damage at baseline (SHS; p < .001). SF, but not serum, 14-3-3η levels correlated with absolute progression ( p < .03). Conclusion: 14-3-3η levels are significantly higher in RA SF than in serum in an established RA cohort. Serum and SF 14-3-3η levels correlate with radiographic damage at baseline and at 2-years follow-up. This study further substantiates the utility of 14-3-3η as a biomarker for mechanistic joint damage in established RA.